Indian Peptides Market: Patent Expiry of Blockbuster Peptides
The report “Peptide and Anticoagulant Drugs Market by
Type (Hormonal (Insulin, Teriparatide, Calcitonin), Antibioctic (Colistin,
Cycloserine), Low molecular weight heparin (Enaxaparin Sodium, Heparin Sodium),
Application (Diabetes, Cancer) – India Forecast to 2022”, The Indian
peptides market is projected to reach USD 883.0 Million by 2022 from USD
381.8 Million in 2016, at a CAGR...
Indian Peptides Market is expected to register a CAGR of 15.0%
Increasing prevalence of chronic diseases such as diabetes, cancer, and osteoporosis and favorable government policies for the pharmaceutical sector are expected to drive the growth of Indian peptide drugs market.
[85 Slides Report] The Indian Peptides Market is expected to reach USD 883.0 Million in 2022 from USD 381.8 Million in 2016 and is expected to register a CAGR of 15.0%.
Indian...
Indian Peptide Drugs Market | Rising Aging Population
According to the latest research report “Peptide and Anticoagulant Drugs Market by
Type (Hormonal (Insulin, Teriparatide, Calcitonin), Antibiotic (Colistin,
Cycloserine), Low molecular weight heparin (Enoxaparin Sodium, Heparin Sodium),
Application (Diabetes, Cancer) – India Forecast to 2022” published by
MarketsandMarkets.
The Indian
peptide drugs market is expected to reach USD 883.0...
Indian Peptides and Heparin Market: Favorable Government Initiatives for the Pharmaceutical Sector
Increasing prevalence of chronic diseases such as diabetes,
cancer, and osteoporosis and favorable government policies for the
pharmaceutical sector are expected to drive the growth of Indian peptide drugs
market.
The growing incidence of coagulation disorders and
government support for pharmaceutical companies are expected to drive the
growth of Indian anticoagulant drugs market.
How much...
The Indian Peptides and Heparin Market by Type & Application – 2022
the Indian peptide drugs market is segmented into type and application. This market is expected to reach USD 883.0 million by 2022 from USD 381.8 million in 2016, at a CAGR of 15.0%. Increasing prevalence of chronic diseases such as cancer and diabetes and favorable government policies for the pharmaceutical sector are the major factors driving the growth of Indian peptide drugs market. For instance,...